Please assess the completion status of the following clinical trial:

Trial Title: Clinical Trial of the Treatment of Acute Sinusitis With Standard-dose Versus High-dose Amoxicillin/Clavulanate

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Adult 18 or over~2. Meets definition of acute sinusitis by Infectious Disease Society of America (2012)~3. Clinician and participant chose to start antibiotic treatment~Exclusion Criteria:~1. Previously enrolled in the study~2. Allergic or intolerant to amoxicillin, penicillin, or amoxicillin/clavulanate~3. Specific medication concerns: lactating (since safety of clavulanate unknown); taking allopurinol (increased risk of rash); concurrent mononucleosis (increased risk of rash with amoxicillin); chronic kidney disease with glomerular filtration rate \< 30; significant hepatic impairment; history of antibiotic-associated colitis~4. Cognitive impairment so that unable to give informed consent or give reliable assessment of improvement~5. Need to use high-dose amoxicillin/clavulanate: treatment with amoxicllin or penicillin within the past month (risk of penicillin-resistant pneumococci), very ill patient (though not ill enough to send to hospital); immunocompromise~6. Need to hospitalize the patient

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- standard dose (Type: ACTIVE_COMPARATOR): amoxicillin/clavulanate 875/125 mg + placebo tablet twice a day for 7 days
- high dose (Type: EXPERIMENTAL): Time Period I (November 18, 2014-January 5, 2016): extended-release amoxicillin/clavulanate 1000/62.5 mg 2 tablets (by different manufacturer) twice a day for 7 days Time Period 2 (February 6, 2016-February 27, 2017): immediate-release amoxicillin/clavunate 875/125 mg plus standard immediate-release amoxicillin 875 mg twice a day for 7 days

Based on this trial design, predict the completion outcome and termination type (if applicable).